Press Room
ɫAV invests $170 million in new capacity and capabilities
ɫAV, the global leader in spray drying and particle engineering, today announced that it is expanding its industrial facilities around the world to support its ambitious growth objectives
Jean-Luc Herbeaux, COO, andGuy Villax, CEO at CPhI Worldwide, in Milan.
Milan, 10th November, 2021 – ɫAV, the global leader in spray drying and particle engineering, today announced that it is expanding its industrial facilities around the world to support its ambitious growth objectives. The company has been on an expansion track since 2016 in Portugal, Ireland and New Jersey with the aim of continuing to increase its capacity and capabilities to address customer needs.
The announcement of a $170 million investment in ɫAV units in Portugal, Ireland, and New Jersey, leading to a global capacity increase of approximately 25%, was made at CPhI Worldwide, in Milan, by Guy Villax, CEO, and Jean-Luc Herbeaux, COO.
These investments will be used to support growth in the company´s pharma custom development and manufacturing service business, fueled by strongly growing demand for ɫAV´s integrated and differentiated services in drug substance manufacturing, particle engineering and most recently drug product manufacturing.The expansion will go hand-in-hand with a build-up of ɫAV´s global team with the creation of more than 300 new jobs globally. This strategy will allow the company to continue to address difficult-to-meet client needs while reinforcing its commitment to the ɫAV values and standard of quality.
In the USA, ɫAV will add a 2900m2 building next to its current facility in East Windsor, New Jersey, laying the foundations for a state-of-the-art ɫAV Campus. The upcoming cycle of investment will bring additional commercial spray drying capacity online by 2023. Further investments will follow with the aim to solidify the company´s integrated offer: API - Particle - Drug Product in the region.This expansion will allow ɫAV to accompany existing and new customers favoring US-based manufacturing through their development cycles all the way to commercial.
The capacity and capabilities of ɫAV´s Cork site in the Republic of Ireland will also be upgraded to enable the production of Highly Potent Active Pharmaceutical Ingredients (HPAPI) and to facilitate onboarding of Drug Substance Manufacturing projects of all sizes.The investment will create an ecosystem in which large customer projects with unique technologies can find a home by connecting to the existing infrastructure and equipment. The site will also receive a new commercial size spray dryer to support the growing demand for particle engineering services.
In Portugal, ɫAV is ready to start operations of its most recent facility with an increase in chemical synthesis capacity for High Potency Active Pharmaceutical Ingredients (HPAPI). The building is also prepared to receive a new commercial spray dryer to respond to the future needs of the global drug market.
“ɫAV is in it for life and what better way to manifest this than through expansion of our global capacity and capabilities. Our sustainable organic growth strategy will allow us to keep true to those values that have been guiding us for more than 60 years”, says Guy Villax, Chief Executive Officer.
“These investments reinforce our integrated specialized offer globally, providing our clients with a line of sight for their projects.Focus is placed on facilitating and speeding up the drug development cycle and launch, by providing API manufacturing, Particle Engineering and Tableting services in each site.Our strategy continues to be to grow organically via investments in our existing sites, which are designed for purpose.This reduces the complexity associated with the growth journey and allows us to focus our management attention on what counts most, i.e. guaranteeing that our clients go to market with quality, safe and effective medicines for their patients” says Jean-Luc Herbeaux, ɫAV’s Chief Operation Officer.
About ɫAV:ɫAV is an international company with over 60 years of experience as aContract Development and Manufacturing Organization(CDMO)and is currently a fully integrated supplier offering services fordrug substance,drug product intermediateanddrug product. With fourFDA inspectedsitesin the USA, China, Ireland and Portugal and development laboratories in Lisbon, Portugal and New Jersey, USA, the company provides branded pharmaceutical customers services for thedevelopment and compliant manufactureof innovative drugs including highly potent compounds. For generic pharmaceutical customers the company offers niche API products. In the inhalation area, ɫAV is the only independent company offering a complete range of services.ɫAV is a company with a culture based on innovation, quality and delivery. ɫAV is a member of, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.
